Samsung Biologics clears 87.88% tender hurdle: what it means for Samsung Biologics stock
Published on 10/19/2026 at 02:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTender outcome and operating scale
- Samsung Biologics held 87.92 percent of PolyPeptide voting rights on October 16, 2026.
- Second-quarter 2026 revenue reached KRW 1.3209 trillion, up 30 percent year over year.
- Samsung Biologics stock was quoted at KRW 1,347,000 on its KRX listing on October 19, 2026 at 9:17 a.m. KST.
Samsung Biologics (ISIN KR7207940008) had its PolyPeptide offer declared successful on October 16, 2026, after 87.88 percent of the shares covered by the offer were tendered, according to EQS News. The result clears the minimum acceptance condition while leaving regulatory and corporate approval steps ahead.
Samsung Biologics was quoted at KRW 1,347,000 on its KRX listing on October 19, 2026 at 9:17 a.m. KST. The same market snapshot put its market capitalization at KRW 62.7 trillion, with a 52-week range of KRW 1,150,000 to KRW 1,987,000.
Three milestones frame the deal
On July 17, 2026, Samsung Biologics and PolyPeptide concluded the transaction agreement for the offer, according to the definitive release carried by EQS News. On October 13, 2026, preliminary results showed 87.88 percent of the targeted shares tendered, above the 66.7 percent minimum, as Seoul Economic Daily reported. On October 16, 2026, the definitive result confirmed a 87.92 percent participation rate and an 87.88 percent success rate.
What does the acquisition mean?
The deal adds peptide manufacturing to Samsung Biologics' existing contract development and manufacturing platform. The offer values the transaction at CHF 1.46 billion, while the additional acceptance period runs from October 19 through October 30, 2026, according to EQS News. A shareholder meeting on October 26, 2026, and regulatory approvals remain part of the closing path.
Operating base before expansion
Samsung Biologics reported second-quarter 2026 revenue of KRW 1.3209 trillion and operating profit of KRW 586.4 billion. Revenue increased 30 percent year over year and operating profit rose 23 percent, according to Health Chosun. The company also maintained 2026 revenue growth guidance of 15 percent to 20 percent from the prior year.
Dates for the next decision points
The additional acceptance period ends on October 30, 2026. PolyPeptide has scheduled an extraordinary general meeting for October 26, 2026, to address matters linked to the transaction, according to EQS News. The definitive release says completion is expected toward the end of 2026 or in the first quarter of 2027.
Stock valuation and transaction risk
The market value gives Samsung Biologics substantial scale, but the acquisition still depends on approvals and the completion of the remaining offer conditions. For investors, the key comparison is between the 87.88 percent tender success rate and the 66.7 percent minimum acceptance condition.
Samsung Biologics was quoted at KRW 1,347,000 on its KRX listing on October 19, 2026 at 9:17 a.m. KST. Its 52-week high stood at KRW 1,987,000, leaving the stock below that peak while the PolyPeptide process moves into its next formal stage.
Samsung Biologics stock facts
- Company: Samsung Biologics Co., Ltd.
- ISIN: KR7207940008
- Ticker: 207940
- Primary exchange: KRX
- Latest Korean listing price: KRW 1,347,000 as of October 19, 2026, 9:17 a.m. KST
- Market capitalization: KRW 62.7 trillion as of October 19, 2026
- 52-week range: KRW 1,150,000-1,987,000 as of October 19, 2026
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report KOSPI.
